Gritstone bio stock faces a USD 6 million settlement

Gritstone bio stock is now defined by a proposed USD 6 million securities settlement rather than a clinical milestone, according to a court notice dated September 10, 2026. The document estimates 54.9 million allegedly damaged shares during the settlement class period, putting the legal process at the center of the remaining equity story.

Settlement covers 54.9 million shares

Strategic Claims Services states that the proposed settlement would provide USD 6 million in cash, subject to court approval. Its estimate uses 54.9 million allegedly damaged shares traded during the relevant period, while the modeled average recovery is USD 0.11 per share if all eligible investors participate.

The comparison is stark: the proposed settlement amount is USD 6 million, while the document applies different loss formulas to purchases made from March 9, 2023, through April 1, 2024. For investors, the case now has a defined dollar amount and a defined share-count framework, not merely an open-ended claim.

Bankruptcy changes the equity picture

A September 2026 discussion by LinkedIn says Gritstone entered bankruptcy after building a neoantigen prediction platform and reports that its assets changed hands for USD 21.25 million. That figure is separate from the USD 6 million securities settlement and should not be treated as equity value.

Another biotechnology analysis published in August 2026 describes Gritstone as having filed for Chapter 11 with USD 61.7 million in cash. The source also explains that creditors rank ahead of equity holders in a bankruptcy process, making the legal priority structure more important than the former clinical pipeline valuation.

Court date sets the next checkpoint

The settlement hearing is scheduled for December 4, 2026, at 10:00 a.m. PT, according to the September 10 court notice. The date gives the case a concrete procedural checkpoint, while the USD 0.11 modeled recovery provides the clearest per-share comparison in the filing.

Gritstone bio's investor page continues to list its individualized neoantigen immunotherapy programs and prior corporate releases. The company identity remains linked to biotechnology and cancer vaccine development, but the settlement amount, affected-share estimate, and bankruptcy priority now provide the most concrete framework for understanding the security.